Please ensure Javascript is enabled for purposes of website accessibility

U.S. Marijuana Sales Should More Than Double to $22 Billion by 2022

By Sean Williams - Jul 7, 2019 at 11:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One Wall Street analyst just upped his firm's outlook for domestic retail cannabis sales.

In case you haven't noticed, the legal cannabis industry is turning into a big-money business.

As recently as 2014, the global cannabis industry was just a seed that was beginning to find its roots. The duo of Arcview Market Research and BDS Analytics notes that worldwide licensed-store sales (i.e., legal sales that don't include cannabinoid pharmaceutical sales and general store cannabidiol revenue) were "only" $3.4 billion in 2014.

However, in 2018, global licensed-store sales surpassed $10 billion for the first time in history. And this could be just the beginning. With more U.S. states looking to legalize recreational marijuana in 2020 -- the United States is considered the crown jewel of the cannabis legalization movement -- and more countries giving medical marijuana the OK, the outlook for legal marijuana is certainly looking greener.

In fact, things are looking so good that one Wall Street firm recently raised its outlook for U.S.-based marijuana sales.

A clear jar packed with cannabis buds that's sat atop a fanned pile of twenty dollar bills.

Image source: Getty Images.

U.S. pot sales could more than double by 2022

In a research note released early last week, Canaccord Genuity analyst Bobby Burleson forecast that legal-channel U.S. sales would hit roughly $22 billion by 2022. According to Barron's, which first reported on Burleson's note to clients, the Canaccord analyst had previously predicted a compound annual growth rate (CAGR) of 19% between 2019 and 2022, but has since upped his (and his firm's) outlook to a CAGR of 20%. Either way, Burleson's U.S. retail sales target implies a better-than-doubling of marijuana sales in the U.S. between 2018 and 2022.

The impetus for the stronger outlook appears to be Illinois becoming the 11th state to legalize adult-use marijuana. Democratic Gov. J.B. Prtizker signed the decriminalization bill into law in late June, and Illinois is on track to begin recreational weed sales on Jan. 1, 2020. Burleson wound up lifting his 2020 sales estimate for Illinois to $488 million from $277 million following the announcement, with a CAGR forecast of 66% between 2019 and 2022 for the Land of Lincoln.

Despite tax-related issues in California that have allowed illicit producers and retailers to thrive, the Canaccord analyst also foresees that state hitting $5.6 billion in legal-channel pot sales by 2022. Burleson fully expects that California will crack down on illicit producers, which should be a positive for companies operating within legal channels.

Interestingly, though, Burleson doesn't foresee New York becoming a recreationally legal state until 2022, and he makes no mention of New Jersey pushing for adult-use cannabis anytime soon. Burleson does, however, see the potential for higher sales estimates in the Garden State following the recent expansion of its medical marijuana program. 

A large marijuana store sign, with a cannabis leaf and the word dispensary written underneath it.

Image source: Getty Images.

A double-edged sword for U.S.-focused marijuana stocks

If Burleson's prognostication proves even remotely accurate, it would appear that the premiums being bestowed on multistate cannabis stocks make sense.

Vertically integrated dispensary store operators like Curaleaf Holdings (CURLF -1.21%), MedMen Enterprises (MMNFF -11.49%), Cresco Labs (CRLBF 1.10%), Harvest Health & Recreation (HRVSF), and iAnthus Capital Holdings (ITHUF 5.97%), have been aggressively expanding into new states, and making costly acquisitions to infiltrate new markets and acquire new retail, grow farm, and processing licenses.

To rattle off a few examples:

  • Curaleaf is buying the Select brand from Cura Partners for about $950 million in an all-stock deal.
  • MedMen is in the midst of buying privately held PharmaCann for the tidy sum of $682 million in an all-stock acquisition.
  • Cresco Labs is ponying up $823 million in an all-stock deal to purchase cannabis distribution license holder Origin House (ORHOF) (based on the share price when the acquisition was first announced).
  • Harvest Health agreed to buy privately held Verano Holdings for approximately $850 million in an all-stock deal.
  • iAnthus Capital completed a nearly $600 million deal to buy MPX Bioceutical earlier this year, thereby expanding its reach.

MedMen's purchase of PharmaCann will give it access to the Illinois market, Harvest Health will have access to 17 total states, and Cresco's acquisition of Origin House means getting its in-house-branded products into more than 500 California dispensaries. The simple point being that these deals, while pricey, are bringing brand-name U.S.-focused pot stocks into many of the most promising U.S. markets.

Unfortunately, there is a price to be paid for this expansion -- and  investors might foot the bill.

A visibly frustrated stock trader that's grasping his head while looking at losses on his computer screen.

Image source: Getty Images.

With the exception of Curaleaf and MedMen, most of these U.S. dispensary stocks are only operating a handful of stores at the moment, which means the only real source of cash to fund acquisitions and retail-level expansion is common stock issuances. Although there's been plenty of appetite in the investment community for these newly issued shares, the impact on existing shareholders remains markedly negative.

A ballooning outstanding share count weighs on longtime shareholders, and it can adversely impact earnings per share (EPS) for profitable pot stocks -- a worry that won't really impact this group of stocks until 2020. Nevertheless, a rising share count does mean that future EPS estimates may be too optimistic.

Each and every one of the deals described above is being financed with common stock issuances. And in many instances, the value of the deal works out to a significant percentage of each company's current market cap. For instance, Cresco's proposed buyout of Origin House would exchange 0.8428 Cresco shares for each Origin share held by investors. That means the value of the deal would be more than half of Cresco Labs' current market cap, which means plenty of dilution for shareholders. 

Likewise, iAnthus's already-completed deal to buy MPX Bioceutical   has created a company with nearly 800 million Canadian dollars in assets, but a ghastly CA$555 million in goodwill that it may never recoup.

In short, while plenty of opportunity does exist for the burgeoning U.S. marijuana market, investors in U.S.-focused companies may not benefit as much as they expect.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Origin House Stock Quote
Origin House
Cresco Labs Inc. Stock Quote
Cresco Labs Inc.
$3.94 (1.10%) $0.04
iAnthus Capital Stock Quote
iAnthus Capital
$0.09 (5.97%) $0.01
MedMen Enterprises Stock Quote
MedMen Enterprises
$0.10 (-11.49%) $0.01
Curaleaf Holdings, Inc. Stock Quote
Curaleaf Holdings, Inc.
$5.84 (-1.21%) $0.07
Harvest Health & Recreation Inc. Stock Quote
Harvest Health & Recreation Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.